UBS Group
ACRV icon

UBS Group’s Acrivon Therapeutics ACRV Stock Holding History

UBS Group’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.1K Sell
34,634
-313,907
-90% -$548K ﹤0.01% 7391
2025
Q4 		$840K Sell
348,541
-334,677
-49% -$728K ﹤0.01% 5719
2025
Q3 		$1.24M Buy
683,218
+682,763
+150,058% +$960K ﹤0.01% 5379
2025
Q2 		$541 Sell
455
-12,433
-96% -$17.1K ﹤0.01% 9796
2025
Q1 		$26.2K Sell
12,888
-1,329
-9% -$7.16K ﹤0.01% 8038
2024
Q4 		$85.6K Buy
14,217
+8,555
+151% +$62.2K ﹤0.01% 6971
2024
Q3 		$39.6K Sell
5,662
-5,490
-49% -$43.3K ﹤0.01% 6968
2024
Q2 		$64.7K Sell
11,152
-1,593
-12% -$12.8K ﹤0.01% 6482
2024
Q1 		$91.1K Buy
+12,745
New +$59.2K ﹤0.01% 6268
2023
Q4 		– Sell
-102
Closed -$975 – 9232
2023
Q3 		$975 Sell
102
-9,678
-99% -$112K ﹤0.01% 8197
2023
Q2 		$127K Buy
9,780
+4,384
+81% +$53.1K ﹤0.01% 5826
2023
Q1 		$68.5K Buy
5,396
+648
+14% +$10.9K ﹤0.01% 6198
2022
Q4 		$54.7K Buy
+4,748
New +$60.3K ﹤0.01% 6681

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's ACRV Position: Q1 2026 in Review

UBS Group reduced its Acrivon Therapeutics (ACRV) stake by 90% in Q1 2026, selling an estimated $548K and leaving 34,634 shares worth $48.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7391.

UBS Group first reported a position in ACRV in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.24M in Q3 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • UBS Group held 34,634 shares of Acrivon Therapeutics worth $48.1K as of Q1 2026.
  • UBS Group sold 313,907 Acrivon Therapeutics shares in Q1 2026, an estimated $548K.
  • Acrivon Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7391 holding.
  • UBS Group first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • UBS Group's Acrivon Therapeutics position peaked at $1.24M in Q3 2025.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.